Search company, investor...
AN2 Therapeutics company logo

AN2 Therapeutics

an2therapeutics.com

Founded Year

2017

Stage

IPO | IPO

Total Raised

$92M

Date of IPO

3/25/2022

Market Cap

0.21B

Stock Price

11.02

About AN2 Therapeutics

An2 Therapeutics (NASDAQ: ANTX) is focused on the research, development, and commercialization of medicines targeting infectious diseases.

Headquarters Location

1800 El Camino Real Suite D

Atherton, California, 94027,

United States

650-331-9090

Missing: AN2 Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AN2 Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AN2 Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AN2 Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest AN2 Therapeutics News

Lennar To Rally Around 14%? Plus Keybanc Predicts $5,120 For This Stock - Advanced Micro Devices (NASDAQ:

Nov 14, 2022

Benzinga By Lisa Levin Keybanc boosted the price target on Lennar Corporation LEN from $89 to $100. Lennar shares fell 0.4% to close at $88.03 on Friday. Keybanc raised NVR, Inc. NVR price target from $4,800 to $5,120. NVR shares fell 0.9% to close at $4,491.44 on Friday. Keefe, Bruyette & Woods cut Barings BDC, Inc. BBDC price target from $10.5 to $10. Barings BDC shares rose 0.7% to close at $9.16 on Friday. UBS boosted the price target on Advanced Micro Devices, Inc. AMD from $75 to $95. AMD shares rose 2.3% to $74.04 in pre-market trading. SVB Leerink cut the price target for AN2 Therapeutics, Inc. ANTX from $27 to $25. AN2 Therapeutics shares gained 1.2% to close at $14.87 on Friday. Needham cut the price target on Montrose Environmental Group, Inc. MEG from $60 to $48. Montrose Environmental shares gained 4.1% to close at $47.90 on Friday. DA Davidson cut the price target for Sally Beauty Holdings, Inc. SBH from $14.5 to $11.5. Sally Beauty shares gained 3.7% to close at $13.34 on Friday. AD

AN2 Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AN2 Therapeutics Rank

AN2 Therapeutics Frequently Asked Questions (FAQ)

  • When was AN2 Therapeutics founded?

    AN2 Therapeutics was founded in 2017.

  • Where is AN2 Therapeutics's headquarters?

    AN2 Therapeutics's headquarters is located at 1800 El Camino Real, Atherton.

  • What is AN2 Therapeutics's latest funding round?

    AN2 Therapeutics's latest funding round is IPO.

  • How much did AN2 Therapeutics raise?

    AN2 Therapeutics raised a total of $92M.

  • Who are the investors of AN2 Therapeutics?

    Investors of AN2 Therapeutics include Hatteras Venture Partners, BVF Partners, Avidity Partners, RA Capital Management, Monashee Investment Management and 7 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.